2,2-difluoro-N-methylethanamine | 60168-06-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,2-difluoro-N-methylethanamine
• 英文别名: (2,2-Difluoroethyl)(methyl)amine
• CAS: 60168-06-1
• 化学式: C₃H₇F₂N
• mdl: MFCD11212379
• 分子量: 95.0921
• InChiKey: BFIDWKHKCDJLQE-UHFFFAOYSA-N

物化性质

• 沸点：
  32.5±35.0 °C(Predicted)
• 密度：
  0.968±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2-difluoro-N-methylethanamine 、 ethyl 7-chloro-1-(2,4-difluorophenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 96.0h， 以84%的产率得到ethyl 7-[(2,2-difluoroethyl)(methyl)amino]-1-(2,4-difluorophenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate
  参考文献：
  名称：

  POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR

  摘要：

  本申请涉及肌动蛋白M2受体的阳性变构调节剂，特别是新型的7-取代的1-芳基萘啶-3-羧酰胺，以及其制备方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。

  公开号：

  US20180297994A1
• 作为产物：
  描述：

  N-benzyl-N-(2,2-difluoroethyl)-N-methylamine 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 14.5h， 生成 2,2-difluoro-N-methylethanamine
  参考文献：
  名称：

  MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: Exploration of aromatic substituents

  摘要：

  A series of 4-oxo-4H-pyrido[1,2-a]pyrimidine derivatives, derivatized at the 2-position with aromatic substituents, were synthesized by the Suzuki cross-coupling method and evaluated for their ability to potentiate the activity of the fluoroquinolone levofloxacin (LVFX) and the anti-pseudomonas beta-lactam aztreonam (AZT) in Pseudomonas aeruginosa. By incorporating hydrophilic substituents onto the aryl nucleus, we found a morpholine analogue that possessed improved solubility, retained activity in vitro, and displayed potentiation activity in vivo in a rat model of P. aeruginosa pneumonia. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.08.037

文献信息

• [EN] 2-METHYL-QUINAZOLINES<br/>[FR] 2-MÉTHYL-QUINAZOLINES
  申请人：BAYER PHARMA AG

  公开号：WO2018172250A1

  公开（公告）日：2018-09-27

  The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.

  本发明描述了一般式(I)的2-甲基喹唑啉化合物，制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的药物组合物和组合物，以及用于制造药物组合物的该化合物的用途。一般式(I)的2-甲基取代喹唑啉化合物有效且选择性地抑制Ras-Sos相互作用，而不显著靶向EGFR受体。因此，它们对于治疗或预防疾病特别是高增殖性疾病，如癌症作为单一药剂或与其他活性成分组合使用是有用的。
• [EN] 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES<br/>[FR] 3-AMINO-1,5,6,7-TÉTRAHYDRO-4H-INDOL-4-ONES
  申请人：BAYER PHARMA AG

  公开号：WO2016202755A1

  公开（公告）日：2016-12-22

  Compounds of formula (I) as described hereinprocesses for their production and their use as anti-cancer agents.

  本文描述的式(I)化合物，其生产方法及其作为抗癌药物的用途。
• [EN] HETEROARYLAMIDE INHIBITORS OF TBK1<br/>[FR] INHIBITEURS HÉTÉROARYLAMIDE DE TBK1
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2016057338A1

  公开（公告）日：2016-04-14

  Disclosed are compounds of formula (1): which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.

  公开的是式（1）的化合物：这些化合物可用作TBK1的抑制剂。还公开了含有这些化合物的药物组合物，用于治疗与TBK1相关疾病的方法，以及制备这些化合物及其中间体的方法。
• NOVEL COMPOUNDS
  申请人：PRIEPKE Henning

  公开号：US20120149676A1

  公开（公告）日：2012-06-14

  This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E 2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 9 , R a , R b have meanings given in the description.

  本发明涉及公式I的化合物，它们用作微粒体前列腺素E2合成酶-1（mPGES-1）的抑制剂，包含它们的制药组合物以及它们用作治疗和/或预防炎症性疾病和相关症状的药物。其中A、L、M、W、R1、R2、R3、R4、R6、R7、R9、Ra、Rb的含义在说明中给出。
• Compounds
  申请人：Priepke Henning

  公开号：US08674113B2

  公开（公告）日：2014-03-18

  This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, R9, Ra, Rb have meanings given in the description.

  本发明涉及公式I的化合物，它们的用途是作为微粒体前列腺素E2合成酶-1（mPGES-1）的抑制剂，包含它们的制药组合物，并将它们用作治疗和/或预防炎症性疾病及相关病症的药物。其中，A、L、M、W、R1、R2、R3、R4、R6、R7、R9、Ra、Rb的含义详见说明。